BRCA1 and BRCA2 Mutations
Hereditary mutations in the BRCA1 and BRCA2 genes are a major risk factor for the development of several cancers, particularly breast and ovarian cancer. These genes encode proteins involved in DNA repair through homologous recombination, a crucial mechanism that maintains genomic stability by correcting double-strand DNA breaks.
When a pathogenic variant (i.e., a harmful mutation) disrupts the function of these genes, the cell’s ability to repair DNA damage is compromised, leading to genomic instability and an increased likelihood of malignant transformation.
Clinical Relevance
Carrying a pathogenic BRCA1 or BRCA2 mutation significantly increases cancer risk. For instance, women with a BRCA1 mutation have up to a 65% lifetime risk of developing breast cancer, while those with a BRCA2 mutation face a slightly lower but still substantial risk.
In addition to breast cancer, these variants are also associated with a higher risk of ovarian cancer, and to a lesser extent with prostate, pancreatic, and male breast cancers.
From a diagnostic and therapeutic standpoint, identifying BRCA1/2 mutations is crucial — it enables enhanced clinical surveillance, preventive strategies, and targeted treatments, such as PARP inhibitors, as well as consideration of prophylactic interventions.
Key Considerations for Laboratories and Genetic Counseling
- Genetic testing should be conducted in accredited laboratories, and all detected variants must be interpreted according to standardized international guidelines (e.g., ACMG/AMP).
- Many variants of uncertain significance (VUS) still exist for BRCA1/2, meaning that a negative result does not fully exclude genetic risk, and not every detected variant implies a clear clinical pathway.
- Genetic counseling should integrate personal and family medical history, individual phenotype, and implications for relatives. Preventive and screening strategies — including prophylactic surgery and pharmacological prevention — must be personalized.
In Summary
Pathogenic BRCA1 and BRCA2 mutations are central to the hereditary predisposition to breast and ovarian cancers. Their detection allows for tailored prevention and monitoring programs and has direct implications for treatment decisions. However, genetic interpretation remains complex, requiring a careful assessment of variant classification, family genetics, and clinical context.